Yes this is a job for an MDM2 inhibitor since the problem is not p53 mutation. Which is why this study uses RITA, an MDM2 inhibitor. Kevetrin may be effective here if its theorized MDM2-phosphorylation properties hold up, which would be exciting.
Very interesting. Have you sent that to Cellceutix? The CEO appears to be receptive to following up on worthwhile due diligence provided by shareholders. It's not entirely out of the question that they might feel your find is worth further investigation. Thanks for sharing.